InvestorsHub Logo
Followers 0
Posts 12
Boards Moderated 0
Alias Born 12/13/2012

Re: None

Wednesday, 09/09/2015 7:52:00 AM

Wednesday, September 09, 2015 7:52:00 AM

Post# of 3987
Moving nicely pre-market on 8k:

CARMIEL, Israel, September 9, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim data from the Company’s phase I/II clinical trial of 1mg/kg of PRX-102 for the treatment of Fabry disease. PRX-102 is a recombinant plant cell expressed, chemically modified version of the human alpha-Galactosidase-A enzyme.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News